AI assistant
FDC Ltd. Earnings Release 2025
60812_rns_2025-05-29_5c8dfad4-3175-4bc7-abe2-58818189f8a9.pdf
Earnings Release
Open in viewerOpens in your device viewer
MANUFACTURERS & EXPORTERS OF FOODS, DRUGS & CHEMICALS
Date:- May 29, 2025
To, Mumbai- 400 001 Mumbai - 400051
BSE Limited National Stock Exchange of India Ltd. Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot no. C/1, G Block, Dalal Street, Bandra-Kurla Complex, Bandra (E),
BSE Script Code: 531599 NSE Symbol: FDC
Sub: Press Release on Q4 - FY 2024-25 and 12M - FY 2024-25 Results.
Dear Sir/Ma'am,
Please find attached herewith the Press Release issued in relation to the Audited Standalone and Consolidated Financial Results of the Company for the Quarter and Year ended March 31, 2025.
Kindly take the same on record.
Thanking you,
Yours truly For FDC Limited VARSHAR ANI KATRE Digitally signed by VARSHARANI KATRE Date: 2025.05.29 11:03:20 +05'30'
Varsharani Katre Company Secretary & Compliance Officer M No.: FCS-8948
| CCORPORATE OFFICE | :142-48,S. V. Road, Jogeshwari (W), Mumbai - 400 102. INDIA | |
|---|---|---|
| Tel.: +91-22-6291 7900 / 950 / 2678 0652 / 2653 / 2656 ® Fax : +91-22-2677 3462 | ||
| E-mail : fdc@{dcindia.com Website : www.fdcindia.com |
||
| REGISTERED OFFICE | B-8, M.LD.C. Industrial Area, Waluj - 431 136, Dist. Aurangabad. INDIA | |
| Tel.: 0240-255 4407 / 255 4299 / 255 4967 » Fax : 0240-255 4299 | ||
| E-mail : [email protected] e CIN : L24239MH1940PLC003176 |
MANUFACTURERS & EXPORTERS OF FOODS, DRUGS & CHEMICALS
FDC Limited reports Q4FY25 results
Mumbai, 28" May 2025: FDC Limited (NSE: FDC, BSE: 531599, ISIN: INE258B01022) reported financials for the fourth quarter ended 31% Mar 2025.
Consolidated Q4FY25 FDC and FY25 reported
| Q4FY25 | Q4FY24 | YoY = Grw |
||||
|---|---|---|---|---|---|---|
| Operating Revenue | 492 | 462 | 6.5% | 2,108 | 1,943 | 8.5% |
| EBITDA | 54 | 56 | -4.2% | 325 | 339 | -4.1% |
| EBITDA % | 11.0% | 12.2% | 15.4% | 17.4% | ||
| PBT | 53 | 65 | -18.3% | 357 | 396 | -9.8% |
| PAT | 39 | 46 | -16.5% | 267 | 305 | -12.5% |
| EPS (Rs.) | 2.38 | 2.84 | -16.5% | 16.39 | 18.58 | -11.8% |
Commenting on the results;
We're pleased to share that your Company crossed the 22,000 crore revenue mark in FY25, growing 8.5% to reach 32,108 crore. This milestone reflects the continued strength of our India Formulations business, which contributed 84% of sales and growing with 14.4% YoY, and strong momentum in our API segment, which grew 21.1% YoY. Export Formulation business however reported decline of 25.6% YoY primarily due to lower sales in US market and few of the ROW markets. Lower sales in US market were majorly due to regulatory issues. The regulatory issues of US market have now been addressed, and management believe the business should be back in its normal flow in the coming financial year.
CORPORATE OFFICE :142-48, S. V. Road, Jogeshwari (W), Mumbai - 400 102, m\DPn:/ Tel.: +91-22-3071 9100 - 399 / 2678 0652 / 2653 / 2656 ® Fax : +91-22-2678 6393 / 8123 / 1912 E-mail: [email protected] ® Website : www.fdcindia.com
REGISTERED OFFICE : B-8, M.L.D.C. Industrial Area, Waluj - 431 136, Dist. Aurangabad. INDIA
Tel.: 0240-255 4407 / 255 4299 /255 4967 » Fax : 0240-255 4299 E-mail : [email protected] e CIN : L24239MH1940PLC003176
FDC Limited No.
Profitability during the year was impacted primarily due to drop in the Export formulation business, reduction in price of Electral due to NLEM price revision announcement during QI1FY25, and higher employee costs in view of moderate expansion in field force in certain clusters of India market.
Business-wise Sales Performance
| XCr | Q4FY25 | YoY Grw | FY25 | ||
|---|---|---|---|---|---|
| Net Sales | 492 | 6.5% | 2,108 | ||
| India Formulations | 415 | 16.7% | 1,773 | ||
| US Formulations | 10 | -74.4% | 63 | ||
| Emerging Markets | 36 | -4.2% | 155 | ||
| API Sales | 30 | 11.5% | 112 |
India Market:
The sale of branded formulations in India for Q4FY25 was Rs. 415 crores, with a growth of 16.7% on YoY and up by 7.0% over QoQ. For FY25, sales were at Rs. 1,773 crores, a healthy growth of 14.4% over FY24. Overall sales in the Indian market accounted for 85% of total consolidated sales for the quarter and 84% for FY25.
As per secondary sales data by IQVIA for the quarter ended Mar 31, 2025, the Company delivered YoY growth of 15.5% compared to the Indian Pharmaceutical Market (IPM) growth of 7.3% YoY. Electral has moved up to 15" rank in IPM in MAT Mar'25 as compared to 22™ in the same period last year.
Further, the company was the 2™ fastest growing company as per MAT Mar'25 among the Top 25 companies, supported majorly by flagship brand Electral, Zifi and Enerzal.
Export Formulations Market:
Formulation Sales in the Export market were Rs. 46 crores in Q4FY25, down by 39.2% over YoY and lower by 3.6% over QoQ and accounted for 9% of total consolidated sales. FY25 Sales were Rs. 218 crores, down by 25.6% over FY24.
Regulatory issues which contributed to drop in US formulation business have been addresses in later part of Q4FY25 and management believes the growth momentum in Export formulation business to be back in the coming financial year.
FDC Limited No.
API Business:
API business showed good traction of growth momentum with sales of Rs. 30 crores in Q4FY25, up by 11.5% over YoY and up by 7.4% over QoQ and accounted for 6% of total consolidated sales. During FY25, the API business grew by 21%, registering sales of Rs. 112crs.
ABOUT FDC LTD
FDC was established in the year 1936 as a partnership firm. This firm was incorporated as a Company in 1940, with the vision of building a world-class company while contributing to making the nation self-reliant in healthcare. To cite a few, FDC carries forward the flaming spirit of its first dream, achieving accreditations from the US-FDA, UK-MHRA, MCC-RSA, and the UAE. FDC is a forerunner in the manufacturing and marketing of Oral Rehydration Salts (ORS), anti-infectives and ophthalmic. FDC has also set up globally approved, multi-location manufacturing facilities for Active Pharmaceuticals Ingredients (APIs) as well as Finished Dosage Forms. These facilities are located at Roha, Waluj and Sinnar in Maharashtra, Verna in Goa and Baddi in Himachal Pradesh. FDC markets more than 300 products in India and exports many of these to over 50 countries. FDC strives to explore, innovate and integrate solutions with modern technology, empowering talent and expanding healthcare horizons for a better quality of life for millions globally.
Disclaimer
Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve several risks and uncertainties including the impact of Covid-19 and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy. our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, fluctuation in earnings, foreign exchange rates, our ability to manage international operations and exports, our exposure to market risks as well as other risks.
